# Herbalife to Report Q3 Results Monday as Analysts Expect Revenue Growth of 2.8%

> Herbalife reports Q3 results Monday afternoon, with analysts expecting revenue to rise 2.8% year on year.

- Published: 2026-11-01T03:46:17+00:00
- Section: Earnings & Results
- Author: News Desk
- URL: https://newsforagent.com/news/2026-11-01/herbalife-q3-earnings-revenue-growth
- Source: [TradingView](https://www.tradingview.com/news/stockstory:5953d452e094b:0-herbalife-hlf-q3-earnings-what-to-expect/)

## Key takeaways

- Herbalife will announce Q3 results Monday afternoon, with the market expecting revenue to grow 2.8% year on year.
- Herbalife reported $1.33 billion in revenue last quarter, up 5.4% year on year, but missed analysts' EPS estimates.
- Analysts have an average price target of $17 for Herbalife, compared with a current share price of $12.99.

[Herbalife](https://akta.pro/company-profiles/0000vf2/herbalife) will report third-quarter results Monday afternoon, with the market expecting revenue to grow 2.8% year on year, according to [TradingView](https://www.tradingview.com/news/stockstory:5953d452e094b:0-herbalife-hlf-q3-earnings-what-to-expect/). The nutrition company beat revenue expectations last quarter at $1.33 billion, up 5.4% year on year, but missed analysts' EPS estimates.

## Herbalife's Revenue Outlook and Last Quarter

Herbalife sells meal replacement shakes, sports nutrition, supplements and personal care products through a network of more than 2 million independent distributors across 90+ markets, according to [company records](https://akta.pro/company-data). The expected 2.8% growth compares with the 2.7% increase Herbalife recorded in the same quarter last year.

Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business will stay the course heading into earnings. Herbalife has missed Wall Street's revenue estimates multiple times over the last two years. Last quarter was mixed: full-year EBITDA guidance slightly topped analysts' expectations, while EPS fell well short.

Among consumer staples peers that have already reported, Medifast's revenues decreased 19.4% year on year, beating analysts' expectations by 1%, and Vita Coco reported revenues up 33.7%, topping estimates by 6.1%. Medifast traded up 5.1% following its results, while Vita Coco was down 11%.

## Herbalife's Refinancing and First-Quarter Sales

Herbalife priced $800 million of 7.75% senior secured notes due 2033 in April 2026 as part of a $1.45 billion refinancing package, reducing leverage from 4.1x to 3.1x and earning an S&P upgrade to BB- from B+, according to akta.pro company records. The same records show Q1 2026 net sales of $1.317 billion, with revenue up 7.8% year on year and full-year guidance reaffirmed. Herbalife reported approximately $5.0 billion in full-year net sales for 2025.

## Herbalife's Analyst Ratings and Red Cross Renewal

In October 2026, Herbalife received multiple analyst rating updates, including upgrades to strong-buy and a new $21 price target from UBS, Defense World reported. Wall Street Zen downgraded the stock to hold, while Citigroup reaffirmed a buy with a $17 target. On October 27, Herbalife renewed its $1 million in-kind commitment to the American Red Cross Blood Saves Lives program, providing protein bars and bites for blood donors, PR Newswire reported.

## Herbalife's Monday Results

MarketBeat reported that Herbalife is expected to report Q3 2026 earnings after market close on November 2, 2026, with analysts projecting $0.6180 EPS and $1.31 billion revenue. TradingView said the results will come Monday afternoon.

## Companies in this story

- [Herbalife company profile](https://akta.pro/company-profiles/0000vf2/herbalife) · website: https://www.herbalife.com

---
News for Agent · https://newsforagent.com/llms.txt